Seven anonymised accounts of real early-stage university R&D and IP projects. What we were working with, where it got hard, what we learned, and how each one changed the way PIPE works.
Every project we take on teaches us something. Some lessons confirm what we suspected. Others only emerge after months of careful work, difficult conversations, and the occasional dead end. The accounts below are drawn from real projects, anonymised and condensed. They are an honest record of what we have learned about moving early-stage university R&D and IP from the bench towards commercial reality.
A research team at a British university had developed a novel thermochemical energy storage device — in effect, a high-density thermal battery charged using existing electric vehicle infrastructure. Rather than storing energy as electricity, the system stores it as heat and cold via a reversible chemisorption process, then uses it to manage cabin temperature and thermal loads independently of the primary battery pack. The claimed benefit was an improvement in EV driving range of up to 70%, alongside extended battery lifespan and reduced HVAC energy draw.
The project arrived with genuinely exciting science and a compelling headline number. Translating that number into a credible commercial proposition proved considerably harder than it first appeared. The primary difficulty was market positioning. The device could, in principle, serve EV range extension, domestic heating, industrial thermal management, and grid-adjacent storage. Trying to address all of these simultaneously is a classic early-stage trap.
This project made clear that no matter how robust the commercialisation process, it cannot substitute for direct industry engagement. The experience directly informed our decision to develop a formal corporate partnering programme.
A university researcher had developed a novel integrated circuit design for reading the quantum state of silicon qubits — a critical but poorly solved problem in the race to build scalable quantum computers. The invention used a capacitance-based detection principle implemented in standard silicon CMOS. The readout circuitry was roughly 100 times smaller per qubit than the dominant LC resonator approach and consumed as little as 61 microwatts at operating frequency.
This was one of the most technically sophisticated and commercially complex projects we have engaged with. The quantum computing sector was, as one correspondent put it, very fluid. Multiple competing hardware approaches were in play and no dominant architecture had emerged. The ARM licensing model was intellectually compelling but required a library of IP, not a single patent. Building that library required further prototyping, further research, and further investment.
The experience shaped our thinking about how the PIPE Associate Network should work and what kinds of capital structures are needed to support very early-stage deep tech.
A university research team had developed a novel unsupervised detection system for identifying advanced persistent threats hidden within the normal network traffic of enterprise applications. The system, built on a combination of Continuous Time Hidden Markov Models and Time Series Decomposition, was designed to detect beaconing — the regular, low-frequency communications that compromised machines send back to attacker-controlled servers.
The technology was strong and the problem it solved was real. The challenge was one of commercialisation framing, not scientific validity. The cybersecurity market is crowded and fast-moving. Enterprise buyers are sceptical of academic research that has not been hardened into production-grade software, and the gap between validated on benchmark datasets and deployable in a live enterprise environment is substantial.
Working through this project contributed directly to the development of the Disclosure and Validation Report as a standard output for all projects we assess.
A university team had developed a compact, portable device designed to objectively measure the hand tapping test used in clinical assessment of Parkinson’s disease. The device records tap count, inter-tap intervals, and dwell time during a standard thirty-second test, feeding the data into a custom software platform for analysis and transfer to clinicians, enabling remote and continuous monitoring between appointments.
The technology was well conceived and the clinical rationale was sound. The challenge was not whether the device was useful — it was how to get it into clinical practice. The NHS adoption pathway for MedTech is long, structured, and resource-intensive. A device at the boundary between consumer health technology and regulated medical device faces a particularly complex journey.
Working with this project made it clear that the standard PIPE QED framework, whilst effective across a wide range of sectors, needed to be extended for MedTech. We subsequently developed additional structured streams within the QED framework to handle sectors with their own mandatory processes.
A research team had developed an AI-driven framework for recovering critical materials from end-of-life solar panels and equipment. The problem was real and urgent. The global installed base of solar photovoltaic panels is ageing rapidly, and the materials within them — including silver, indium, tellurium, and high-purity silicon — are both strategically valuable and increasingly difficult to source.
The technology portfolio was broad and genuinely innovative, but it comprised several distinct commercial opportunities bundled into a single proposition. AI-driven recycling, novel solar cell architecture, and solid-state battery anodes each represent a different technology, a different market, and a different competitive and regulatory landscape. Attempting to commercialise all three simultaneously made it impossible to present a clear, compelling investment case.
This project was one that would have benefited from early, informal exposure to industry experts before it entered the formal Disclosure and Validation stage. The experience contributed directly to our thinking about what is now Stage 0 of the Lab to IPO Pathway.
A multidisciplinary university team — combining analytical chemists, chemometricians, and clinicians — had developed a methodology applying metabolomics to the perioperative investigation of complex congenital heart disease, with a particular focus on Fontan disease. A key innovation was the use of commercially available blood micro-sampling devices, dramatically reducing patient burden compared with conventional blood collection. This was particularly significant for paediatric patients and for patients in rural or under-resourced settings.
This was one of the most genuinely affecting projects we have worked with. The clinical need is profound, the patient population is vulnerable, and the team’s commitment to patient experience showed a rare alignment between scientific innovation and human-centred design. The primary difficulty was the regulatory and clinical validation pathway, which for a diagnostic or monitoring tool used in the perioperative care of children with complex congenital heart disease is necessarily demanding.
Projects of this kind made clear we needed access to a broader and more diverse range of capital than conventional venture funding provides. The funding infrastructure we have built since reflects that need.
A university research team had developed a biological methanation process capable of converting carbon dioxide and green hydrogen into synthetic methane using a microbial catalyst. The process is anaerobic and operates via a biochemical reaction in which microorganisms consume CO&sub2; and H&sub2; and produce CH&sub4;, at conversion efficiencies the team had measured at approximately 98% under laboratory conditions. The technology had been evaluated across multiple reactor configurations and part-funded by Innovate UK, BBSRC, and BEIS.
The project arrived with a genuine head of steam. The science was well validated and the team had been thorough in their technical documentation. Yet despite this productivity, the fundamental commercial questions remained genuinely open. The team could articulate what the process did with considerable precision — who would pay for it, on what terms, and via what commercial structure was harder to answer. Gas grid injection in the UK is a particularly demanding route to market and, at the point of engagement, those regulations were themselves in flux.
We declined a request to produce a report that would support the next tranche of public funding rather than reflect our actual conclusions. External, independent commercial review should happen before public funds are committed, not after. Universities and their technology transfer teams should be willing to trust the findings of external partners even when those findings are uncomfortable.
The PIPE framework was not designed in a meeting room. It was built project by project, from the questions that were not answered and the gaps that commercial reality exposed.
Systematic validation at every stage. The QED framework applies structured Go/No-Go assessment across commercial, environmental and societal dimensions before any resource is committed. Sector-specific streams for MedTech, Legal & Governance, and Customer Discovery were built directly from project experience.
Explore QED →An informal first step before full disclosure. Born from projects that arrived at the formal process carrying assumptions that should have been tested earlier. One paragraph, fingerprinted, community reviewed, and no inventive step required.
Post a Napkin Idea →A structured marketplace from incubation to listing. Projects that successfully complete the PIPE incubation pathway can be listed on the PIPExchange, securing future funding rounds with no upper limit, all the way through to full IPO.
Explore PIPExchange →All projects described above have been anonymised. Names of researchers, institutions and commercial partners have been removed or generalised. labtoipo.info · The PIPE Company OÜ (UK) Limited · 2026
Whether you have a fully formed innovation or just a napkin sketch, there is a place on the PIPE pathway for where you are right now.